

Amendments to the Claims


This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently amended) A method to normalize the contractile response of ~~an endothelially-compromised vascular smooth muscle cell in response to a vasoconstrictor agonist~~ vasculature in a patient in need of such normalization, the vasculature comprising a vascular smooth muscle cell layer and a compromised endothelial cell layer, wherein the method comprising ~~comprises~~ administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof.
- 2-5. (Cancelled)
6. (Previously Presented) A method of claim 23, wherein the compound administered is 1-p- β -dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, or a pharmaceutically acceptable salt thereof.
7. (Previously presented) A method of claim 23, wherein the patient has diabetes.
8. (Previously presented) A method of claim 23, wherein the patient has had a surgical procedure.
9. (Previously presented) A method of claim 23, wherein the patient has hypertension.
10. (Previously presented) A method of claim 23, wherein the patient has coronary artery disease.
11. (Previously presented) A method of claim 23, which further comprises administering a pharmaceutically-effective compound selected from the group consisting of: an anti-diabetes agent; an anti-hypertension agent; an anti-coronary artery disease agent; and an anti-restenosis agent.

12-22. (Cancelled)

23. (Previously presented) A method of claim 1, wherein the CLC3 blocker is a compound of
Formula I



wherein

either R⁴ is H or a lower alkyl radical and R⁵ is a lower alkyl radical, or R⁴ and R⁵ are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

R⁶ is H or a lower alkyl radical;

R⁷ is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

R⁸ is H or OH; and

n is 2;

or a pharmaceutically acceptable salt thereof.

24. (Cancelled)

25. (Currently Amended) A method to normalize the contractile response of ~~an endothelially-compromised vascular smooth muscle cell vasculature~~ in response to a vasoconstrictor agonist in a patient in need of such normalization, the vasculature comprising a vascular smooth muscle cell layer and a compromised endothelial cell layer, wherein the method

Applicant : Fred S. Lamb
Serial No. : 09/512,926
Filed : February 25, 2000
Page : 4 of 10

Attorney's Docket No.: 17023-010001 / N9-19

~~comprising~~ comprises administering a pharmaceutically effective amount of a CLC3 blocker,
or a pharmaceutically acceptable salt thereof, and wherein the vasoconstrictor agonist is
norepinephrine, ~~KCl or serotonin~~.